Clinical Trials Logo
  1. Home
  2. Acute Mountain Sickness
  3. NCT05023941

Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide

Acute Mountain Sickness Clinical Trial

Official title:
Optimization Strategy for the Prevention of Acute Mountain Sickness by Remote Ischemic Preconditioning Combined With Acetazolamide

Clinical Trial Summary

The primary objective of the study will be to determine whether rapid remote limb ischemic preconditioning (RIPC) combined with acetazolamide can further reduce the incidence of acute mountain sickness (AMS) during the 6-hour hypoxic chamber.

Clinical Trial Description

The current measures to prevent acute mountain sickness (AMS) mainly include drug prevention and non-drug prevention. Acetazolamide is a drug approved by the U.S. FDA for the prevention and treatment of AMS. Remote limb ischemic preconditioning (RIPC) can also reduce the incidence of AMS as a non-durg method, with a strategy of 2 times/day training for 1 week reducing the incidence of AMS in 6 hours from 40% to 30%. The objective of this study is to determine whether rapid RIPC training combined with acetazolamide can further reduce the incidence of AMS. In this study, subjects will be divided into 5 groups: medicine group (acetazolamid 125mg bid, 2 days before entering the hypoxic room), RIPC group (RIPC training twice daily, 6 days before entering the hypoxic room), rapid RIPC group (RIPC training forth daily, 3 days before entering the hypoxic room), combined group (rapid RIPC training plus acetazolamide) and controlled group. RIPC training, completed by Renqiao Remote Ischemic Conditioning Device (Doctormate®), will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. After the intervention, subjects will be exposed to 4500m altitude in a normobaric hypoxic chamber for 6 hours. The incidence of AMS and other data will be compared between groups. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05023941
Study type Interventional
Source Capital Medical University
Contact
Status Completed
Phase Phase 4
Start date December 1, 2021
Completion date August 30, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04111263 - Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude N/A
Completed NCT01842906 - Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) N/A
Completed NCT01536288 - Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Phase 2
Completed NCT00326703 - Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort N/A
Completed NCT06310642 - Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness Phase 4
Completed NCT03561675 - Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Phase 4
Completed NCT00559832 - Prevention of Acute Mountain Sickness by Intermittent Hypoxia N/A
Completed NCT00603122 - Acclimatization Mechanisms During Ascent to 7500m N/A
Completed NCT01436383 - Oxidative Stress in Hypobaric Hypoxia N/A
Completed NCT00664001 - Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness Phase 3
Completed NCT00627965 - Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness Phase 4
Not yet recruiting NCT06145113 - The Effect of Continuous Positive Pressure Ventilation on Symptoms of Acute Mountain Sickness N/A
Recruiting NCT05733338 - The Effects of Intermittent Hypoxia on Acute Hypoxic Injury N/A
Completed NCT01522326 - Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness N/A
Recruiting NCT06393998 - CO2 Supplement for Treatment of Acute Mountain Sickness N/A
Completed NCT03270787 - Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Phase 1/Phase 2
Completed NCT02811016 - Inhaled Budesonide and Acute Mountain Sickness Phase 1
Recruiting NCT00886912 - Training in Hypoxia to Prevent Acute Mountain Sickness N/A
Terminated NCT03956472 - Alternative Treatments in Acute Mountain Sickness N/A
Recruiting NCT03621410 - T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent Phase 2